Manipulation of the ECB system through indirect agonists that increase concentrations of AEA and 2-AG has become a major focus of recent research as a more efficient therapeutic target for depression and anxiety-like disorders than direct agonists of CB1R [124]. Here, CNR1 is linked to depressive symptom measurement.